
This AOP is licensed under a Creative Commons Attribution 4.0 International License.
Aop: 36
Title
Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
Short name
Graphical Representation
Point of Contact
Contributors
- Brian Chorley
- Michelle Angrish
- Lyle Burgoon
Status
Author status | OECD status | OECD project | SAAOP status |
---|---|---|---|
Under Development: Contributions and Comments Welcome | 1.29 | Under Development |
This AOP was last modified on June 04, 2021 10:56
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Decreased, PPAR-alpha activation | September 16, 2017 10:14 |
Decreased, PPAR-beta activation | September 16, 2017 10:14 |
Decreased, PPAR-gamma activation | September 16, 2017 10:14 |
Accumulation, Fatty acid | September 16, 2017 10:14 |
Decreased, HSD17B10 expression | September 16, 2017 10:14 |
Decreased, Mitochondrial fatty acid beta-oxidation | September 16, 2017 10:14 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | September 16, 2017 10:14 |
Increased, Liver Steatosis | March 07, 2019 09:49 |
Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid | December 03, 2016 16:37 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation | December 03, 2016 16:37 |
Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | December 03, 2016 16:37 |
Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression | December 03, 2016 16:37 |
Accumulation, Fatty acid leads to Increased, Liver Steatosis | December 03, 2016 16:37 |
Abstract
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 231 | Decreased, PPAR-alpha activation | Decreased, PPAR-alpha activation |
MIE | 232 | Decreased, PPAR-beta activation | Decreased, PPAR-beta activation |
MIE | 233 | Decreased, PPAR-gamma activation | Decreased, PPAR-gamma activation |
KE | 327 | Accumulation, Fatty acid | Accumulation, Fatty acid |
KE | 140 | Decreased, HSD17B10 expression | Decreased, HSD17B10 expression |
KE | 179 | Decreased, Mitochondrial fatty acid beta-oxidation | Decreased, Mitochondrial fatty acid beta-oxidation |
KE | 8 | Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity | Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
AO | 459 | Increased, Liver Steatosis | Increased, Liver Steatosis |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Overall Assessment of the AOP
Consider the following criteria (may include references to KE Relationship pages): 1. concordance of dose-response relationships; 2. temporal concordance among the key events and adverse effect; 3. strength, consistency, and specificity of association of adverse effect and initiating event; 4. biological plausibility, coherence, and consistency of the experimental evidence; 5. alternative mechanisms that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP; 6. uncertainties, inconsistencies and data gaps.